TOPARP: Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer
- Conditions
- Advanced Castration Resistant Prostate CancerMedDRA version: 18.0Level: LLTClassification code 10036910Term: Prostate cancer NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Registration Number
- EUCTR2011-000601-49-GB
- Lead Sponsor
- The Institute of Cancer Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Male
- Target Recruitment
- Not specified
1.Capable of understanding and complying with the protocol requirements and has signed the informed consent document
2.Age = 18 years
3.Histologically confirmed adenocarcinoma of the prostate with archival tumour tissue available for molecular analyses. If the patient does not have a prior histological diagnosis then the planned baseline fresh biopsy may be used for both the purpose of confirming the histological diagnosis prior to trial entry and for subsequent biomarker analyses
4.At least one but no more than two previous taxane-based chemotherapy regimens. If docetaxel chemotherapy is used more than once, this will be considered as one regime. Patients may have had prior exposure to cabazitaxel treatment
5.At least 28 days since the completion of prior therapy, including major surgery, chemotherapy and other investigational agents. Additionally, clinically relevant sequelae should have resolved to grade 1 or less prior to recommencing treatment. For hormonal treatment and radiotherapy refer to the guidelines below:
•At least 28 days since the completion of prior flutamide treatment. Patients whose PSA did not decline in response to antiandrogens given as a second line or later intervention will only require a 14 days washout prior to Cycle 1, Day 1
•At least 42 days since the completion of prior bicalutamide (Casodex) and nilutimide (Nilandron) treatment. Patients whose PSA did not decline for 3 or 4 months in response to antiandrogens given as second line or later intervention will require only a 14 day washout period prior to Cycle 1 Day1
•At least 14 days from any radiotherapy with the exception of a single fraction of radiotherapy for the purposes of palliation (confined to one field) is permitted
6.Documented prostate cancer progression as assessed by the investigator with one of the following:
•PSA progression defined by a minimum of three rising PSA levels with an interval of = 1 week between each determination. The PSA value at the Screening visit should be = 2 µg/L (2 ng/ml); patients on systemic glucorticoids for control of symptoms must have documented PSA progression by PCWG22 while on systemic glucocorticoids prior to commencing Cycle1 Day1 of treatment
•Radiographic progression of soft tissue disease by modified RECIST criteria or of bone metastasis with two or more documented new bone lesions on a bone scan with or without PSA progression
7.Surgically or medically castrated, with testosterone levels of < 50 ng/dL (< 2.0 nM). If the patient is being treated with LHRH agonists (patient who have not undergone orchiectomy), this therapy must have been initiated at least 4 weeks prior to Cycle 1 Day 1 and must be continued throughout the study
8.Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2 (Karnofsky Performance Status = 50%)
9.Life expectancy > 12 weeks
10.Patient must be able to swallow a whole tablet
11.Patient and the patient’s partner of childbearing potential, must agree to use medically accepted methods of contraception during the course of the study and for 3 months after the last dose of study drug
12.Agreeable to have all the biomarker studies including the paired fresh tumour biopsies
13.Subjects must have a CTC count of =5 cells/7.5mls blood at screening confirmed by the central laboratory. For part B of the study, the minimum CTC count at screening is not mandatory if the patient has measurable disease according to modified RECIST1.1 >2 cms in size at screening a
1.Surgery, or local prostatic intervention (excluding a prostatic biopsy) less than 28 days of Cycle 1 Day 1.
2.Less than 28 days from any active anticancer therapy or investigational agents. For hormonal treatment and radiotherapy refer to the guidelines outlined in the inclusion criteria.
3.Prior treatment with a PARP inhibitor, platinum, cyclophosphamide or mitoxantrone chemotherapy.
4.Uncontrolled intercurrent illness including, but not limited to, active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV heart disease), unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements.
5.Any acute toxicities due to prior chemotherapy and / or radiotherapy that have not resolved to a NCI-CTCAE v4.02 grade ?1 with the exception of chemotherapy induced alopecia and grade 2 peripheral neuropathy.
6.Malignancy within the previous 2-years with a > 30% probability of recurrence within 12 months with the exception of non-melanoma skin cancer, in-situ or superficial bladder cancer.
7.Patients with myelodysplastic syndrome/acute myeloid leukaemia.
8.Patients with known symptomatic brain metastasis are not suitable for enrolment. Patients with asymptomatic, stable, treated brain metastases are eligible for study entry.
9.Patients with symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable and asymptomatic.
10.Patients who experience a seizures within 6 months of study treatment or who are currently being treated with cytochrome P450 enzyme inducing anti-epileptic drugs for seizures (use of anti-epileptic drugs to control pain is allowed in patients not suffering from seizures unless drug is excluded due to CYP3A4 induction - phenytoin, carbamazepine, phenobarbital.
11.Patients receiving any of the following classes of inhibitors of CYP3A4;
-Azole antifungals
-Macrolide antibiotics
-Protease inhibitors
12.Patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
13.Initiating bisphosphonate therapy or adjusting bisphosphonate dose/regimen within 30 days prior to Cycle 1 Day 1. Patients on a stable bisphosphonate regimen are eligible and may continue.
14.Presence of a condition or situation, which, in the investigator’s opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient’s participation in the study.
15.The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method